Paraneoplastic pemphigus: a clinical, laboratorial, and therapeutic overview

Imagem de Miniatura
Arquivos
art_MARUTA_Paraneoplastic_pemphigus_a_clinical_laboratorial_and_therapeutic_overview_2019.PDF (544.48 KB)
Citações na Scopus
26
Tipo de produção
article
Data de publicação
2019
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SOC BRASILEIRA DERMATOLOGIA
Autores
Autor de Grupo de pesquisa
Citação
ANAIS BRASILEIROS DE DERMATOLOGIA, v.94, n.4, p.388-398, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Paraneoplastic pemphigus is a rare and severe autoimmune blistering disease characterized by mucocutaneous lesions associated with benign and malignant neoplasms. Diagnostic criteria include the presence of chronic mucositis and polymorphic cutaneous lesions with occult or confirmed neoplasia; histopathological analysis exhibiting intraepidermal acantholysis, necrotic keratinocytes, and vacuolar interface dermatitis; direct immunofluorescence with intercellular deposits (IgG and C3) and at the basement membrane zone (IgG); indirect immunofluorescence with intercellular deposition of IgG (substrates: monkey esophagus and simple, columnar, and transitional epithelium); and, autoreactivity to desmogleins 1 and 3, desmocollins 1, 2, and 3, desmoplakins I and II, envoplakin, periplakin, epiplakin, plectin, BP230, and alpha-2-macroglobulin-like protein 1. Neoplasias frequently related to paraneoplastic pemphigus include chronic lymphocytic leukemia, non-Hodgkin lymphoma, carcinomas, Castleman disease, thymoma, and others. Currently, there is no standardized treatment for paraneoplastic pemphigus. Systemic corticosteroids, azathioprine, mycophenolate mofetil, cyclosporine, rituximab, cyclophosphamide, plasmapheresis, and intravenous immunoglobulin have been used, with variable outcomes. Reported survival rates in 1, 2, and 5 years are 49%, 41%, and 38%, respectively.
Palavras-chave
Autoantibodies, Autoimmunity, Paraneoplastic syndromes, Pemphigus, Skin diseases, vesiculobullous
URI
https://observatorio.fm.usp.br/handle/OPI/33994
Referências
  1. Al Zamel G, 2015, SPEC CARE DENT, V35, P143, DOI 10.1111/scd.12093
  2. Amagai M, 1998, J CLIN INVEST, V102, P775, DOI 10.1172/JCI3647
  3. Amber KT, 2016, BRIT J DERMATOL, V174, P461, DOI 10.1111/bjd.14234
  4. Amber KT, 2018, AUTOIMMUN REV, V17, P1002, DOI 10.1016/j.autrev.2018.04.008
  5. Anhalt GJ, 2004, J INVEST DERM SYMP P, V9, P29, DOI 10.1111/j.1087-0024.2004.00832.x
  6. ANHALT GJ, 1990, NEW ENGL J MED, V323, P1729, DOI 10.1056/NEJM199012203232503
  7. Aoi J, 2013, J DERMATOL, V40, P285, DOI 10.1111/1346-8138.12095
  8. Barnadas MA, 2006, J EUR ACAD DERMATOL, V20, P69, DOI 10.1111/j.1468-3083.2005.01345.x
  9. Baykal C, 2018, J EUR ACAD DERMATOL, V32, pE50, DOI 10.1111/jdv.14500
  10. Bech R, 2013, BRIT J DERMATOL, V169, P469, DOI 10.1111/bjd.12324
  11. Billet SE, 2006, AUTOIMMUNITY, V39, P617, DOI 10.1080/08916930600972099
  12. Borradori L, 1998, J INVEST DERMATOL, V111, P338, DOI 10.1046/j.1523-1747.1998.00280.x
  13. Borradori L, 2001, ARCH DERMATOL, V137, P269
  14. Broussard KC, 2016, CLIN DERMATOL, V34, P205, DOI 10.1016/j.clindermatol.2015.11.006
  15. Chan LS, 2000, ARCH DERMATOL, V136, P663, DOI 10.1001/archderm.136.5.663
  16. Chen XJ, 2004, J NEUROL, V251, P1006, DOI 10.1007/s00415-004-0479-z
  17. Choi Y, 2012, J DERMATOL, V39, P973, DOI 10.1111/j.1346-8138.2012.01655.x
  18. Czernik A, 2011, INT J DERMATOL, V50, P905, DOI 10.1111/j.1365-4632.2011.04868.x
  19. Decaux J, 2018, J STOMATOL ORAL MAXI, V119, P506, DOI 10.1016/j.jormas.2018.06.003
  20. Dong YJ, 2009, LEUKEMIA LYMPHOMA, V50, P1308, DOI 10.1080/10428190903060095
  21. Ekback M, 2012, LEUKEMIA RES, V36, pE190, DOI 10.1016/j.leukres.2012.04.016
  22. Eming R, 2015, J DTSCH DERMATOL GES, V13, P833, DOI 10.1111/ddg.12606
  23. Frew JW, 2011, DERMATOL CLIN, V29, P607, DOI 10.1016/j.det.2011.06.016
  24. Frew JW, 2011, DERMATOL CLIN, V29, P419, DOI 10.1016/j.det.2011.03.018
  25. HASHIMOTO T, 1995, J INVEST DERMATOL, V104, P829, DOI 10.1111/1523-1747.ep12607012
  26. Heizmann M, 2001, AM J HEMATOL, V66, P142, DOI 10.1002/1096-8652(200102)66:2<142::AID-AJH1032>3.0.CO;2-0
  27. HELOU J, 1995, J AM ACAD DERMATOL, V32, P441, DOI 10.1016/0190-9622(95)90066-7
  28. Hohwy T, 2004, EUR J HAEMATOL, V73, P206, DOI 10.1111/j.1600-0609.2004.00280.x
  29. HORN TD, 1992, ARCH DERMATOL, V128, P1091, DOI 10.1001/archderm.128.8.1091
  30. Ingen-Housz-Oro S, 2013, ANN DERMATOL VENER, V140, P563, DOI 10.1016/j.annder.2013.04.082
  31. Ishii N, 2015, BRIT J DERMATOL, V173, P59, DOI 10.1111/bjd.13711
  32. Jing L, 2011, CLIN EXP DERMATOL, V36, P752, DOI 10.1111/j.1365-2230.2011.04081.x
  33. Joly P, 2000, J AM ACAD DERMATOL, V43, P619, DOI 10.1067/mjd.2000.107488
  34. Kasperkiewicz M, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.26
  35. Kim SC, 1997, J INVEST DERMATOL, V109, P365, DOI 10.1111/1523-1747.ep12336235
  36. Kimyai-Asadi A, 2001, INT J DERMATOL, V40, P367, DOI 10.1046/j.1365-4362.2001.01169.x
  37. Kitagawa C, 2014, ACTA DERM-VENEREOL, V94, P359, DOI 10.2340/00015555-1742
  38. Kiyokawa C, 1998, J INVEST DERMATOL, V111, P1236, DOI 10.1046/j.1523-1747.1998.00449.x
  39. Lane JE, 2004, PEDIATRICS, V114, pE513, DOI 10.1542/peds.2004-0436
  40. Lee JSS, 2006, INT J DERMATOL, V45, P1093, DOI 10.1111/j.1365-4632.2006.02796.x
  41. Leger S, 2012, ARCH DERMATOL, V148, P1165, DOI 10.1001/archdermatol.2012.1830
  42. Lehman VT, 2015, INT J DERMATOL, V54, P424, DOI 10.1111/ijd.12603
  43. Leis-Dosil VM, 2018, ACTAS DERMO-SIFILOGR, V109, P24, DOI 10.1016/j.ad.2017.05.005
  44. LIU AY, 1993, J AM ACAD DERMATOL, V28, P696, DOI 10.1016/0190-9622(93)70095-B
  45. Liu Q, 2008, BRIT J DERMATOL, V158, P587, DOI 10.1111/j.1365-2133.2007.08361.x
  46. Lo Schiavo A, 2010, CLIN DERMATOL, V28, P337, DOI 10.1016/j.clindermatol.2009.06.018
  47. Mahoney MG, 1998, J INVEST DERMATOL, V111, P308, DOI 10.1046/j.1523-1747.1998.00279.x
  48. Martel P, 2003, J AUTOIMMUN, V20, P91, DOI 10.1016/S0896-8411(02)00092-6
  49. MEYERS SJ, 1992, AM J OPHTHALMOL, V114, P621, DOI 10.1016/S0002-9394(14)74494-0
  50. Mimouni D, 2004, J AM ACAD DERMATOL, V51, P62, DOI 10.1016/j.jaad.2003.11.051
  51. Mimouni D, 2002, BRIT J DERMATOL, V147, P725, DOI 10.1046/j.1365-2133.2002.04992.x
  52. Namba C, 2016, J DERMATOL, V43, P419, DOI 10.1111/1346-8138.13160
  53. Nguyen VT, 2001, ARCH DERMATOL, V137, P193
  54. Nousari HC, 1999, NEW ENGL J MED, V340, P1406, DOI 10.1056/NEJM199905063401805
  55. Nousari HC, 1999, J INVEST DERMATOL, V112, P396, DOI 10.1046/j.1523-1747.1999.00520.x
  56. Numata S, 2013, J INVEST DERMATOL, V133, P1785, DOI 10.1038/jid.2013.65
  57. Oh SJ, 2016, BRIT J DERMATOL, V174, P930, DOI 10.1111/bjd.14293
  58. Ohzono A, 2015, BRIT J DERMATOL, V173, P1447, DOI 10.1111/bjd.14162
  59. Ortolan DG, 2011, CLINICS, V66, P2019, DOI 10.1590/S1807-59322011001200004
  60. OURSLER JR, 1992, J CLIN INVEST, V89, P1775, DOI 10.1172/JCI115781
  61. Paolino G, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122532
  62. Payne AS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.13
  63. PERNICIARO C, 1994, MAYO CLIN PROC, V69, P851, DOI 10.1016/S0025-6196(12)61787-X
  64. Poot AM, 2016, BRIT J DERMATOL, V174, P912, DOI 10.1111/bjd.14282
  65. Poot AM, 2013, BRIT J DERMATOL, V169, P1016, DOI 10.1111/bjd.12479
  66. Reich K, 1999, BRIT J DERMATOL, V141, P739
  67. Rivollier C, 2001, ANN DERMATOL VENER, V128, P644
  68. Romi F, 2007, EUR J NEUROL, V14, P617, DOI 10.1111/j.1468-1331.2007.01785.x
  69. Schepens I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012250
  70. Sonnenberg A, 2007, EXP CELL RES, V313, P2189, DOI 10.1016/j.yexcr.2007.03.039
  71. Takahashi M, 2000, CHEST, V117, P603, DOI 10.1378/chest.117.2.603
  72. Tam PM, 2009, BMJ CASE REP, V2009
  73. Tirado-Sanchez A, 2017, ACTAS DERMO-SIFILOGR, V108, P902, DOI 10.1016/j.ad.2017.04.024
  74. Tsuchisaka A, 2016, J INVEST DERMATOL, V136, P399, DOI 10.1038/JID.2015.408
  75. Vezzoli P, 2008, EXPERT REV CLIN IMMU, V4, P351, DOI 10.1586/1744666X.4.3.351
  76. Wang J, 2005, ARCH DERMATOL, V141, P1285, DOI 10.1001/archderm.141.10.1285
  77. Wang J, 2005, BRIT J DERMATOL, V153, P558, DOI 10.1111/j.1365-2133.2005.06599.x
  78. Wang LC, 2004, LANCET, V363, P525, DOI 10.1016/S0140-6736(04)15539-6
  79. Wang R, 2015, BRIT J DERMATOL, V172, P968, DOI 10.1111/bjd.13525
  80. Williams JV, 2000, BRIT J DERMATOL, V142, P506, DOI 10.1046/j.1365-2133.2000.03365.x
  81. Witte M, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00296
  82. Yong AA, 2013, AUSTRALAS J DERMATOL, V54, P241, DOI 10.1111/j.1440-0960.2012.00921.x
  83. Zhang BX, 2006, J INVEST DERMATOL, V126, P832, DOI 10.1038/sj.jid.5700198
  84. Zhang J, 2011, J CANCER RES CLIN, V137, P229, DOI 10.1007/s00432-010-0874-z

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/53
Artigos e Materiais de Revistas Científicas - LIM/56
Artigos e Materiais de Revistas Científicas - ODS/03